Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.46 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362117 | 1.00 | NOD1 (0.50) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL16620664 | 0.84 | NOD1 (0.61) | NOD1MMP2MMP9FOLH1NAALAD2 | |
| SCHEMBL15958209 | 0.84 | NOD1 (0.61) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13226111 | 0.83 | MAPT (0.52) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL24978634 | 0.83 | MAPT (0.52) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL24978653 | 0.83 | MAPT (0.52) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL24978671 | 0.83 | MAPT (0.52) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL15942692 | 0.83 | MAPT (0.52) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL17040489 | 0.83 | NOD1 (0.49) | NOD1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL16620949 | 0.82 | NOD1 (0.47) | NOD1ALDH1A1MMP2MMP9FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9011880-B2 | Compounds and methods for treating cancer | IGF ONCOLOGY, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140171366-A9 | Compounds and methods for treating cancer | IGF ONCOLOGY, LLC | 2014-06-19 | — | — | US | disclosed |
| US-8501906-B2 | Compounds and methods for treating cancer | IGF ONCOLOGY, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20100303929-A1 | Compounds and methods for treating cancer | IGF ONCOLOGY, LLC | 2010-12-02 | — | — | US | disclosed |
| US-7811982-B2 | Compounds and methods for treating cancer | IGF ONCOLOGY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100216696-A1 | Compounds and methods for treating cancer | MCTAVISH HUGH | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216696-A1 | Compounds and methods for treating cancer | IGF1R, IGFBP1, INSR | NOD1 4193/4885KDM4E 4244/4885MAPT 4649/4885 |
| US-20140171366-A9 | Compounds and methods for treating cancer | IGF1R, IGFBP1, INSR | NOD1 4193/4885KDM4E 4244/4885MAPT 4649/4885 |
| US-20100303929-A1 | Compounds and methods for treating cancer | IGF1R, IGFBP1, INSR | NOD1 4193/4885KDM4E 4244/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.